Fintel on MSN
JP Morgan Initiates Coverage of CRISPR Therapeutics (CRSP) with Overweight Recommendation
Fintel reports that on September 18, 2025, JP Morgan initiated coverage of CRISPR Therapeutics (NasdaqGM:CRSP) with a Overweight recommendation. Analyst Price Forecast Suggests 37.35% Upside As of ...
CRISPR: Is The Selloff Really Over? I guess that's what biotech investors should be familiar with, as the stock of CRISPR Therapeutics AG (CRSP) has truly undergone a roller coaster ride all year, ...
TipRanks on MSN
Morningstar to Acquire CRSP for $375 Million
The latest update is out from Morningstar ( (MORN) ).
On July 30, 2025, Morningstar, Inc. (NASDAQ:MORN) reported its Q2 2025 financial results, highlighting a revenue increase of ...
Zacks.com on MSN
CRISPR Therapeutics AG (CRSP) Falls More Steeply Than Broader Market: What Investors Need to Know
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $60.62, marking a -2.38% move from the previous day.
Morningstar, a Chicago-based financial services firm, has announced plans to acquire the Center for Research in Security ...
As part of the transaction, Morningstar will acquire the CRSP Market Indexes, which are the benchmarks for more than $3 trillion in US equities across market capitalizations, investment styles, and ...
Morningstar has agreed to buy the Center for Research in Security Prices, or CRSP, a provider of historical stock-market data and indexes, from the University of Chicago for $375 million.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback